Article

Launch Therapeutics Selects Medidata AI Intelligent Trials

Partnership optimizes trial planning and efficiency.

Medidata has announced that Launch Therapeutics (Launch Tx) selected Medidata AI Intelligent Trials to support its approach to accelerating clinical trials of late-stage therapies.

Medidata AI Intelligent Trials’ Study Feasibility solution provides Launch Tx with higher assurance that trial planning will improve enrollment and quality. This is done by leveraging country and site-level performance data, and predictive analytics. It’s built on a foundation of data from more than 30,000 clinical trials across a wide array of disease indications representing more than nine million study participants.

Reference

Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development. (2023, April 12). Medidata.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.